Xconomy: Propeller Health, Novartis to Develop Add-On Sensor for Breezhaler
Summary
The agreement, announced on Wednesday, is focused on patients with COPD who live in European countries, says Propeller co-founder and CEO David Van Sickle.Van Sickle says that most of the dozens of inhaled medications currently on the market are now able to connect to Propeller’s digital platform, which combines sensors, mobile apps, and software analytics.“They all have unique challenges, in [areas like] attachment and detection,” Van Sickle says, referring to how Propeller’s sensors connect to inhalers and collect data.“The Breezhaler inhaler is a unique form factor, unlike anything we’ve ever built a sensor for before.” Propeller says the fact that its tools are designed to be used both by patients and care providers can be helpful in getting the two sides to formulate treatment programs together.A trained physician and allergist who worked at GSK before joining Propeller as a senior vice president in November, Stempel plans to continue delving into potential applications for “digital information about day-to-day burden management,” Van Sickle says.
Classifications
AskAI Classifications
LabelsLinked Companies
